Stockscreener 앱 받기
26.94
1.16%
0.31
시간 외 거래:
26.94
전일 마감가:
$26.63
열려 있는:
$26.67
하루 거래량:
181.07K
Relative Volume:
0.30
시가총액:
$970.33M
수익:
$13.00M
순이익/손실:
$-68.87M
주가수익비율:
-12.09
EPS:
-2.2276
순현금흐름:
$-76.68M
1주 성능:
-0.70%
1개월 성능:
+22.51%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$26.02
$27.39
1주일 범위
$25.00
$28.82
52주 변동 폭
$13.88
$33.20
Evommune Inc Stock (EVMN) Company Profile
명칭
Evommune Inc
전화
(650) 223-7745
주소
1841 PAGE MILL RD, PALO ALTO
Compare EVMN vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EVMN
Evommune Inc
|
26.94 | 959.17M | 13.00M | -68.87M | -76.68M | -2.2276 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Evommune Inc Stock (EVMN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-07 | 재개 | Oppenheimer | Outperform |
| 2026-01-22 | 개시 | Oppenheimer | Outperform |
| 2026-01-08 | 개시 | Raymond James | Strong Buy |
| 2026-01-06 | 개시 | H.C. Wainwright | Buy |
| 2025-12-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-12-01 | 개시 | Evercore ISI | Outperform |
| 2025-12-01 | 개시 | Leerink Partners | Outperform |
| 2025-12-01 | 개시 | Morgan Stanley | Overweight |
| 2025-12-01 | 개시 | William Blair | Outperform |
모두보기
Evommune Inc 주식(EVMN)의 최신 뉴스
Evommune Makes Case For MRGPRX2 Inhibition in Migraine - Citeline News & Insights
MRGPRX2: A Novel Target in Migraine Treatment – EVO756’s Potential in Migraine Prophylaxis Explained - Minichart
William Blair Maintains Evommune(EVMN.US) With Buy Rating - Moomoo
Evommune: Differentiated MRGPRX2 Strategy and Upcoming EVO756 Phase IIb Readout Support Buy Rating - TipRanks
Evommune Spotlights EVO756 as Novel Preventive Migraine Therapy - TipRanks
Evommune (EVMN) advances oral MRGPRX2 migraine drug EVO756 toward Phase 2b - Stock Titan
RBC Capital Reaffirms Their Buy Rating on Evommune, Inc. (EVMN) - The Globe and Mail
Evommune (NYSE:EVMN) Stock Price Down 7.2%Here's Why - MarketBeat
Evommune's Chronic-Hives Drug May See Wider Use If Trial Succeeds, RBC Says - marketscreener.com
Today's Analyst Rating Update for EVMN: Maintained at Outperform - GuruFocus
Evommune (NYSE:EVMN) Earns Outperform Rating from Royal Bank Of Canada - MarketBeat
RBC Capital Maintains Evommune(EVMN.US) With Buy Rating, Maintains Target Price $48 - Moomoo
Evommune (EVMN) Institutional Ownership 2026 - MarketBeat
Evommune (NYSE:EVMN) Advances Within Biotechnology Research And Development - Kalkine Media
Oppenheimer Initiates Evommune(EVMN.US) With Buy Rating, Announces Target Price $50 - Moomoo
Evommune (NYSE:EVMN) Shares Up 4.7%Here's What Happened - MarketBeat
Oppenheimer Initiates Coverage on Evommune (NYSE:EVMN) - MarketBeat
Evommune bucked biotech IPO drought and is focused on the long game - Pharma Voice
Oppenheimer initiates Evommune stock rating at Outperform, $50 target By Investing.com - Investing.com Australia
Oppenheimer initiates Evommune stock rating at Outperform, $50 target - Investing.com
Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine - PharmiWeb.com
Capricorn Fund Managers Ltd Acquires Shares of 60,000 Evommune, Inc. $EVMN - MarketBeat
Stock List: Research Stocks from Around the World - GuruFocus
Evommune, Inc. (NYSE:EVMN) Receives Average Recommendation of "Buy" from Analysts - marketbeat.com
Evommune, Inc. Common Stock (NY: EVMN - The Chronicle-Journal
EVMN 8-K & SEC Filings - Yahoo Finance Australia
Evommune, Inc. (EVMN) Stock Price Quote Today & Current Price Chart - Capital.com
Evommune, Inc. (EVMN) Stock Price Quote Today & Current Price Chart | Capital.com Australia - Capital.com
Corvus leads drug developers as index climbs in early 2026 - BioWorld MedTech
Evommune (NYSE:EVMN) Trading Up 10.2%Still a Buy? - MarketBeat
Evommune (NYSE:EVMN) Stock Price Down 7.6%Should You Sell? - marketbeat.com
This Evommune analyst begins coverage on a bullish note; here are top 5 initiations for Wednesday - MSN
Evommune, Inc.(NYSE: EVMN) added to S&P Global BMI Index - MarketScreener
EVMN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Planet Labs (NYSE:PL) Revenue Beats, Lags NYSE Index on Profit - Kalkine Media
Evommune (NYSE:EVMN) Upgraded at Clear Str - MarketBeat
Evommune stock sees RS rating rise to 91 - MSN
Nvidia To Rally Around 79%? Here Are 10 Top Analyst Forecasts For Wednesday - Sahm
Technical Analysis of Evommune, Inc. (NYSE:EVMN) - TradingView
Evommune (EVMN) Insider Trading Activity 2026 - MarketBeat
Analysts Set Expectations for Evommune FY2027 Earnings - MarketBeat
Evommune, Inc.(NYSE: EVMN) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Evommune: Buy Rating Backed by 2026 Catalyst Rich Pipeline and Differentiated MRGPRX2 Dermatology Franchise - TipRanks
H.C. Wainwright cuts Evommune stock price target on dilution - Investing.com UK
H.C. Wainwright cuts Evommune stock price target on dilution By Investing.com - Investing.com India
HC Wainwright Cuts Evommune (NYSE:EVMN) Price Target to $50.00 - MarketBeat
Evommune (EVMN) Stock Forecast and Price Target 2026 - MarketBeat
This Evommune Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
EVMN Stock: HC Wainwright & Co. Lowers Price Target to $50 | EVM - GuruFocus
Evommune Inc (EVMN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):